<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02373254</url>
  </required_header>
  <id_info>
    <org_study_id>656916</org_study_id>
    <nct_id>NCT02373254</nct_id>
  </id_info>
  <brief_title>NSAIDS Versus Opioids in Acute SER II Ankle Fractures</brief_title>
  <official_title>Pain Management With NSAIDS in Acute Ankle Fractures Type Supination, External Rotation (SER) II: A Prospective Randomized, Single Blinded Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate whether NSAIDS are more or less effective in bone&#xD;
      healing than opioids in acute fracture pain. Participants will be randomized to one of three&#xD;
      groups for first line treatment of pain related to the fracture.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pain management in acute fractures is challenging and influenced by several factors&#xD;
      contributing to pain perception. These factors include but are not limited to tissue damage&#xD;
      by the local impact, mechanical stress at the fracture ends, and central perception of the&#xD;
      noxious stimulus. Tissue damage and mechanical stress leads to inflammation and further to&#xD;
      local swelling. Swelling itself is significant contributor in pain development.&#xD;
&#xD;
      Ideal pain management would attack pain development at most sites possible. The current&#xD;
      clinical practice in the US applies a derivate of an opioid analgesic combined with&#xD;
      acetaminophen, thereby influencing pain development at central perception by the opioid&#xD;
      analgesic and acetaminophen and a peripheral analgesic effect of acetaminophen. The exact&#xD;
      mechanism of the peripheral effect is not known.&#xD;
&#xD;
      This clinical practice disregards the positive effect of medications influencing the&#xD;
      peripheral inflammatory response, namely nonsteroidal anti-inflammatory drugs (NSAIDs).&#xD;
      NSAIDs affect pain development by blocking the synthesis of arachidonic acid metabolites,&#xD;
      inhibiting peripheral inflammatory response and central pain perception. The major reason for&#xD;
      not applying NSAIDs in the treatment of acute fracture pain is an experimental animal study&#xD;
      showing decreased bone healing in relation to NSAID usage.&#xD;
&#xD;
      However, clinical data thus far is inconclusive, whether bone healing is affected in humans&#xD;
      and whether NSAIDs should be avoided in the setting of bone fractures.&#xD;
&#xD;
      This proposed study will give an answer whether the usage of NSAIDs in acute fractures has a&#xD;
      negative effect on bone healing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fracture healing as measured by radiographic evaluation</measure>
    <time_frame>12 weeks</time_frame>
    <description>fracture healing at 12 weeks followup</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain level improvement as measured by VAS score</measure>
    <time_frame>1 week, 2 weeks, 6 weeks, 9 weeks and 12 weeks</time_frame>
    <description>VAS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional improvement as measured by AAOS score</measure>
    <time_frame>1 weeks, 2 weeks 6 weeks, 9 weeks and 12 weeks</time_frame>
    <description>AAOS scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Ankle Fracture</condition>
  <arm_group>
    <arm_group_label>Ibuprofen 400 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen 400 mg po q 8 hours as needed (PRN) for pain. Subjects will receive Norco, 5/525 mg po q 6 hours PRN if pain relief with Ibuprofen is not sufficient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen 800 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen 800 mg po q 8 hours PRN pain. Subjects will receive Norco, 5/525 mg po q 6 hours PRN if pain relief with Ibuprofen is not sufficient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Norco</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Norco (acetaminophen/hydrocodone) 10/325 mg po q 6 hours PRN pain. If pain is not relieved, physician should be contacted.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Ibuprofen 400 mg and 800 mg</description>
    <arm_group_label>Ibuprofen 400 mg</arm_group_label>
    <arm_group_label>Ibuprofen 800 mg</arm_group_label>
    <other_name>Motrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen/hydrocodone</intervention_name>
    <description>Norco 5/325 mg and 10/325 mg</description>
    <arm_group_label>Norco</arm_group_label>
    <other_name>Norco</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 to &lt; 60&#xD;
&#xD;
          -  Isolated ankle fracture type SER II&#xD;
&#xD;
          -  Ability to speak and understand English&#xD;
&#xD;
          -  BMI&lt; 35&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ASA&gt;3&#xD;
&#xD;
          -  Previous or acute gastric bleeding&#xD;
&#xD;
          -  Renal insufficiency (Creatinine: &gt;1.27mg/dl)&#xD;
&#xD;
          -  Liver insufficiency (Child-Pugh-Wert: 10-15)&#xD;
&#xD;
          -  Malignant tumor&#xD;
&#xD;
          -  Rheumatoid arthritis&#xD;
&#xD;
          -  Heart failure (NYHA III-IV)&#xD;
&#xD;
          -  High frequency absolute arrhythmia&#xD;
&#xD;
          -  Patients with known psychiatric illness&#xD;
&#xD;
          -  Coagulopathy&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
          -  Function limiting disease of the lower extremity, besides what is mentioned in the&#xD;
             inclusion criteria&#xD;
&#xD;
          -  Adults unable to consent&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Workers Comp patient&#xD;
&#xD;
          -  Early fracture displacement (within first 2 weeks) indicating need for surgery&#xD;
&#xD;
          -  Polytrauma&#xD;
&#xD;
          -  Concurrent participation in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J Steffner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>February 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <last_update_submitted>July 11, 2017</last_update_submitted>
  <last_update_submitted_qc>July 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Ankle Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Acetaminophen, hydrocodone drug combination</mesh_term>
    <mesh_term>Hydrocodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

